Protocol Ledger

NCT06937099 · Phase III · RECRUITING

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Interventional Phase III clinical trial protocol NCT06937099 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-26 Enrollment: 290 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06937099
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)290 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06937099
Protocol FieldVerified Registry Value
NCT IdentifierNCT06937099
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment290 participants (ESTIMATED)
Registered Start Date2025-06-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06937099
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI